Beta Bionics (Nasdaq:BBNX) today reported second-quarter financial results that topped the consensus estimates on Wall Street.
Shares of BBNX remained unmoved at $15.17 apiece after the market closed today.
The Irvine, California-based automated insulin delivery technology developer reported losses of $23.4 million in the quarter. That equals 53¢ per share on sales of $32 million for the three months ended June 30, 2026.
Beta Bionics recorded a nearly $7 million bottom-line slide on a sales increase of 37.8%.
Losses per share landed 3¢ ahead of expectations on Wall Street. Sales also topped the forecasts as experts projected $31.5 million in revenue.
Beta Bionics logged durable medical equipment (DME) channel sales of $20.4 million, up 9% from the same period a year ago. Pharmacy Benefit Plan (PBP) channel sales totaled $11.6 million, rising 153% from the prior year. New patient starts on the iLet Bionic Pancreas increased by 10% year-over-year but marked a 20% decrease sequentially from the first quarter.
Highlights for the quarter included sharing real-world data that highlighted the impact of its iLet Bionic Pancreas platform and setting expectations for a launch of its new Mint patch pump system by the second quarter of 2027.
Beta Bionics reaffirmed its guidance for 2026, including revenue between $131 million and $136 million. It projects 37% to 39% of new patient starts reimbursed through the PBP channel. The company increased the low end of its gross margin projection by 1%, now ranging between 58.5% and 59.5%.
